Furthermore, targeted therapies for several oncogenic alterations, such as PD-L1-positive expression and ALK translocation have been incorporated during the clinical treatment of lung cancers (Imyanitov et al., 2021), Interestingly, higher expression levels of NDC80 were observed if PD-L1>50% LUAD than if it was <50% PD-LI and negative tissues (Figure 6I). The gene discussed is ALK; the disease is lung carcinoma.